NCT04145375Enrolling by invitationPhase 1/2
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Source: ClinicalTrials.gov · Last updated 8 May 2026
Brief summary (registry, in English)
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 28 Oct 2019
- Start date
- 12 Nov 2019
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Zenith Epigenetics
- Diseases
- Prostate cancer
- NCT number
- NCT04145375
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 40
- From 12 Nov 2019 to the primary completion date, 31 Dec 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent participation in another clinical investigational treatment trial
- Require addition of or change to a new concomitant therapy to adequately treat the malignancy under study
Other
- Discontinued ZEN003694 or withdrew consent to participate in original Zenith Epigenetics-sponsored ZEN003694 study
- Any other reason that in the opinion of the Investigator would prevent the patient from completing participation or following the study schedule
Who the study is looking for
- Protocol-defined completion in a parent ZEN003694 trial
- Patient has clinical benefit as determined by the investigator at the time of entry to the continuation protocol
- ECOG performance status of 0 or 1
- Acceptable ZEN003694 tolerability, in the judgment of the investigator
- Initiation of dosing in this continuation trial to occur within two weeks (14 days) of completing dosing in the parent trial, unless more time is approved by the sponsor in writing
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oregon Health Science University Coordinator of this site? Confirm its status | Portland | United States | Unknown status |
| University of California San Francisco Medical Center Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.